Themes 2020

The Central Nervous System

Why are you expecting big advances in the treatment of central nervous system diseases over the next few years?

The greatest biotech treatment advances of the next five or ten years are expected to occur in neuroscience, with novel treatments under development in SMA, Huntington’s, Autism, ALS, DMD, Parkinson’s and Alzheimer’s.

Recent reorganization of the FDA includes establishment of an Office of Neuroscience, driven by FDA’s focus on the great unmet need in this area, and an upcoming wave of new high-technology drug candidate reviews. Given the paucity of treatment options for diseases such as Alzheimer’s, any safe and effective therapy that makes it to market would be widely adopted.

What we’re watching:

  • Biogen’s aducanumab data
  • Roche’s gantenerumab and anti-tau trials
  • FDA regulatory flexibility
  • FDA Office of Neuroscience
Themes 2020

Themes 2020

Download the Handbook
5.8M

People in us suffering from Alzheimer’s

Zero

Meetings of FDA’s peripheral central nervous system drugs advisory committee in 2019

$7.2B

Estimated US TAM for Aducanumab if approved

100+

Alzheimer’s drugs that have failed in previous clinical trials

Research

Podcast

Inclusive & Disruptive Beauty for the Next Generation | e.l.f. Beauty CEO, Tarang Amin & CMO, Kory Marchisotto

Read More
Ahead of the Curve®

Energy Transition, Part VI: Initiating on Next-Generation Fuels

Read More
Ahead of the Curve®

Investor’s Guide to Immuno-Oncology: Focus on Novel Targets

Read More

Events

Boulder, CO / Virtual

Aug 09, 2021

7th Annual Communications Infrastructure Summit

Learn More
Virtual

Jun 16, 2021

6th Annual FutureHealth Conference

Learn More
Virtual

Jun 01, 2021

49th Annual Technology, Media & Telecom Conference

Learn More